Skip to main content
- DC04 – This is a study looking to see if a vaccine that is made from a person’s own white blood cells is safe and if it will result in an increase in the body’s immune system reaction to HIV. The study will be done in people living with HIV who are doing well on HIV medications
- NETI – Safety and Immunogenicity of Recombinant HIV Envelope Protein VRC-HIVRGP096-00-VP (Trimer 4571) vaccine, in HIV-1 Infected Adults on Suppressive ART. Approximately 32 HIV-1-infected men and women ages >18years, maintained on suppressive antiretroviral therapy for a minimum of 24 months with current CD4+ count >200 cells/mm3. Participants will be on study approximately 44 weeks.
- A5359 – This study would like to know if Long-Acting Injectable ART will be more successful for people who are non-adherent to their HIV medications than currently available oral regimens. The main advantages of LA ART in this population include infrequent dosing and directly-observed therapy during the LA ART phase. However, a main challenge for this population is that a participant will need to have their HIV under control (undetectable) on oral medications before they are eligible to switch to LA ART. Financial incentives will be used during the first 20 weeks of the study to help motivate participants to be adherent to an oral regimen until they are eligible to be randomized to either the LA ART arm or the standard of care arm
- A5379 (BEe-HIVe) – B-ENHANCEMENT OF HBV VACCINATION IN PERSONS LIVING WITH HIV
A study looking at hepatitis B vaccination in adults living with HIV. The study will involve individuals who have received a previous hepatitis B vaccination but the vaccine did not respond well and individuals who have never received the vaccination. The study will compare how well an individual responds to the vaccine in different groups based on the type of vaccine and number of doses. Eligible participants on study for 72 weeks
- A5355 CMV Vaccine – The purpose of this study is to see if an investigational vaccine for CMV (called Triplex®) is safe when given to people with both HIV and CMV. This study will also collect information on the effectiveness of Triplex® to reduce inflammation and immune activation markers compared to a placebo. This will be the first time that this type of information will be collected
- A5391 – Doravirine for those with weight gain on integrase inhibitors- This research study is trying to find out if PLWH who had > 10% weight gain after starting an antiretroviral therapy (ART) regimen that included an INSTI in combination with TAF/FTC (or TAF/3TC) could gain less weight, or maybe lose weight, after switching to an ART regimen containing doravirine (DOR) with either TAF/FTC (or TAF/3TC), or the related medication tenofovir disoproxil fumarate/emtricitabine (TDF/FTC [or TDF/3TC])